AGOMELATINE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17NO2
Molecular Weight	243.301
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(CCNC(C)=O)C=CC=C2C=C1

InChI

InChIKey=YJYPHIXNFHFHND-UHFFFAOYSA-N

InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H17NO2
Molecular Weight	243.301
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12750432 | https://www.ncbi.nlm.nih.gov/pubmed/12764576 | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf

Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. Accumulating evidence in a broad range of experimental procedures supports the notion that the psychotropic effects of agomelatine are due to the synergy between its melatonergic and 5-hydroxytryptaminergic effects. Agomelatine is indicated for the treatment of major depressive episodes.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Melatonin receptor 1A 6 Target ID: CHEMBL1945 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Agonist 2752	0.1 nM [Ki]
Melatonin receptor 1B 6 Target ID: CHEMBL1946 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Agonist 2752	0.12 nM [Ki]
Serotonin 2c (5-HT2c) receptor 131 Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Antagonist 2849	6.2 null [pKi]
Serotonin 2b (5-HT2b) receptor 60 Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24724693	Antagonist 2849	6.6 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Major depressive disorder 179 Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf	Primary		Approved 8583	VALDOXAN Approved Use Treatment of major depressive episodes. Launch Date 2009

C_max

Value	Dose	Analyte	Population
211.3 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
176.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
250.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
182.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
385.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
203.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
12.032 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
191 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
283 ng/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.032 ng/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
10.891 ng/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
261.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
236.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
288.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
223.48 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
459.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
403.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
12.795 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.9 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
405 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
539 ng × h/mL OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12.637 ng × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
11.572 ng × h/mL EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
0.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30789308/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
0.813 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
0.9 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3.3 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.4 h OTHER GOV'T https://www.ema.europa.eu/en/documents/assessment-report/valdoxan-epar-public-assessment-report_en.pdf#page=15	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.813 h EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: UNKNOWN sex: MALE food status: FASTED
0.96 h EXPERIMENT https://www.jstage.jst.go.jp/article/cpb/65/6/65_c16-00866/_article	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	AGOMELATINE blood	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28392509/			AGOMELATINE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/	Sources: https://pubmed.ncbi.nlm.nih.gov/14567168/
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/	Sources: https://pubmed.ncbi.nlm.nih.gov/9140018/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438 substrate 1193	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 MRP2 499 MRP3 246 MRP4 290 BSEP 550 CYP2C19 2057	CYP1A2 1197 CYP2C19 1119 P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 24.0	inconclusive [IC50 15.4871 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 25.0	inconclusive [IC50 19.4971 uM]
BSEP 554	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw2MDIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP2 625	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1NzQ4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP3 326	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1OTE4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
MRP4 345	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDEwODc4In19	no [IC50 >133 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 23.0	yes [IC50 15.4871 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 27.0	yes [IC50 34.6713 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 19.0	yes [IC50 4.8975 uM]

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	major
CYP2C19 1119	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	minor
CYP2C9 1193	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	minor
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/30789308/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/82148#section=BioAssay-Results Page: 109.0

PubMed

Title	Date	PubMed
New selective ligands of human cloned melatonin MT1 and MT2 receptors.	2003 Jun	12764576
Gateways to clinical trials. March 2003.	2003 Mar	12731460
Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands.	2003 Mar 27	12646022
[Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders].	2003 Mar-Apr	14567168
Gateways to clinical trials.	2003 Nov	14685303
Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors.	2004 Mar	15069466
Differential effects of the novel antidepressant agomelatine (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain.	2004 Sep	15380370
Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study.	2004 Sep	15289700
Newer treatment studies for bipolar depression.	2005	16225556
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade.	2005 Feb	15289999
Antidepressant action of agomelatine (S 20098) in a transgenic mouse model.	2005 Jul	16005135
Recent advances in melatonin receptor ligands.	2005 Jun	15952241
[Development of a new antidepressant : agomelatine].	2005 Oct	16197911
Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN.	2005 Oct	16139172
Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats.	2005 Oct	15986188
Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.	2005 Sep	16117817
[Depression and neuroplasticity: implication of serotoninergic systems].	2005 Sep-Oct	16433011
Future prospects in depression research.	2006	16889104
Therapeutic potential of melatonin ligands.	2006	16687314
Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.	2006 Aug	16376525
Efficacy and tolerance profile of agomelatine and practical use in depressed patients.	2006 Feb	16436938
Sleep disturbances and depression: a challenge for antidepressants.	2006 Feb	16436937
Clinical efficacy of agomelatine in depression: the evidence.	2006 Feb	16436936
Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system.	2006 Feb	16436935
Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety.	2006 Feb	16377959
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.	2006 Feb	16249073
Agomelatine targets a range of major depressive disorder symptoms.	2006 Jul	16869122
Melatonin: Nature's most versatile biological signal?	2006 Jul	16817850
Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis.	2006 Jun 1	16499883
Prospects for the treatment of depression.	2006 May	16683964
[Agomelatine: the first "melatoninergic" antidepressant].	2006 Oct	17211046
Emerging treatments for major depression.	2007 Feb	17286553
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.	2007 Nov	18052566
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.	2007 Oct	17477888
Promising avenues of therapeutics for bipolar illness.	2008	18689289
Gateways to clinical trials.	2008 Apr	18597009
A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.	2008 Jun	18480691
Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.	2008 Oct	18794654
Innovation translates into antidepressant effectiveness.	2008 Sep	18753277
Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.	2009	19442180
Chronic mild stress (CMS) in mice: of anhedonia, 'anomalous anxiolysis' and activity.	2009	19177164
Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture.	2009 Jul	19370342
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.	2009 Jun	19440080
Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.	2009 Winter	19228178
Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.	2010 Jan	18801825

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 25 mg once daily taken orally at bedtime. After two weeks of treatment, if there is no improvement of symptoms, the dose may be increased to 50 mg once daily, i.e. two 25 mg tablets, taken together at bedtime. Decision of dose increase has to be balanced with a higher risk of transaminases elevation. Any dose increase to 50 mg should be made on an individual patient benefit/risk basis and with strict respect of LFT monitoring.

Route of Administration: Oral

In Vitro Use Guide

hypothalamic suprachiasmatic nucleus firing rates were dose-dependently suppressed by 19.2-80.9% following perfusion of 0.04-0.32mM agomelatine (p<0.001, IC50=0.14mM).

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:15 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:15 GMT 2025`
Record UNII	137R1N49AD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AGOMELATINE

Official Name

English

THYMANAX

Preferred Name

English

AGOMELATINE [MI]

Common Name

English

VALDOXAN

Brand Name

English

S20098

Code

English

Agomelatine [WHO-DD]

Common Name

English

N-(2-(7-METHOXY-1-NAPHTHYL)ETHYL)ACETAMIDE

Systematic Name

English

AGOMELATINE [EMA EPAR]

Common Name

English

agomelatine [INN]

Common Name

English

AGOMELATINE [MART.]

Common Name

English

S-20098

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C66885